Septimus Edward J, Schweizer Marin L
Hospital Corporation of America, Nashville, Tennessee, USA Texas A&M Health Science Center, College of Medicine, Houston, Texas, USA
University of Iowa Carver College of Medicine, Iowa City, Iowa, USA Iowa City VA Health Care System, Iowa City, Iowa, USA University of Iowa College of Public Health, Iowa City, Iowa, USA.
Clin Microbiol Rev. 2016 Apr;29(2):201-22. doi: 10.1128/CMR.00049-15.
Colonization with health care-associated pathogens such as Staphylococcus aureus, enterococci, Gram-negative organisms, and Clostridium difficile is associated with increased risk of infection. Decolonization is an evidence-based intervention that can be used to prevent health care-associated infections (HAIs). This review evaluates agents used for nasal topical decolonization, topical (e.g., skin) decolonization, oral decolonization, and selective digestive or oropharyngeal decontamination. Although the majority of studies performed to date have focused on S. aureus decolonization, there is increasing interest in how to apply decolonization strategies to reduce infections due to Gram-negative organisms, especially those that are multidrug resistant. Nasal topical decolonization agents reviewed include mupirocin, bacitracin, retapamulin, povidone-iodine, alcohol-based nasal antiseptic, tea tree oil, photodynamic therapy, omiganan pentahydrochloride, and lysostaphin. Mupirocin is still the gold standard agent for S. aureus nasal decolonization, but there is concern about mupirocin resistance, and alternative agents are needed. Of the other nasal decolonization agents, large clinical trials are still needed to evaluate the effectiveness of retapamulin, povidone-iodine, alcohol-based nasal antiseptic, tea tree oil, omiganan pentahydrochloride, and lysostaphin. Given inferior outcomes and increased risk of allergic dermatitis, the use of bacitracin-containing compounds cannot be recommended as a decolonization strategy. Topical decolonization agents reviewed included chlorhexidine gluconate (CHG), hexachlorophane, povidone-iodine, triclosan, and sodium hypochlorite. Of these, CHG is the skin decolonization agent that has the strongest evidence base, and sodium hypochlorite can also be recommended. CHG is associated with prevention of infections due to Gram-positive and Gram-negative organisms as well as Candida. Conversely, triclosan use is discouraged, and topical decolonization with hexachlorophane and povidone-iodine cannot be recommended at this time. There is also evidence to support use of selective digestive decontamination and selective oropharyngeal decontamination, but additional studies are needed to assess resistance to these agents, especially selection for resistance among Gram-negative organisms. The strongest evidence for decolonization is for use among surgical patients as a strategy to prevent surgical site infections.
被金黄色葡萄球菌、肠球菌、革兰氏阴性菌和艰难梭菌等医疗保健相关病原体定植与感染风险增加有关。去定植是一种基于证据的干预措施,可用于预防医疗保健相关感染(HAIs)。本综述评估了用于鼻腔局部去定植、局部(如皮肤)去定植、口服去定植以及选择性消化道或口咽部去污的药物。尽管迄今为止进行的大多数研究都集中在金黄色葡萄球菌去定植上,但人们对如何应用去定植策略以减少革兰氏阴性菌尤其是多重耐药菌引起的感染的兴趣日益增加。所综述的鼻腔局部去定植药物包括莫匹罗星、杆菌肽、瑞他帕林、聚维酮碘、酒精基鼻腔消毒剂、茶树油、光动力疗法、五盐酸奥米加南和溶葡萄球菌酶。莫匹罗星仍然是金黄色葡萄球菌鼻腔去定植的金标准药物,但人们担心莫匹罗星耐药性,因此需要替代药物。对于其他鼻腔去定植药物,仍需要大型临床试验来评估瑞他帕林、聚维酮碘、酒精基鼻腔消毒剂、茶树油、五盐酸奥米加南和溶葡萄球菌酶的有效性。鉴于疗效较差且过敏性皮炎风险增加,含杆菌肽的化合物不能作为去定植策略推荐使用。所综述的局部去定植药物包括葡萄糖酸氯己定(CHG)、六氯酚、聚维酮碘、三氯生和次氯酸钠。其中,CHG是有最强证据基础的皮肤去定植药物,次氯酸钠也可推荐使用。CHG与预防革兰氏阳性菌、革兰氏阴性菌以及念珠菌引起的感染有关。相反,不鼓励使用三氯生,目前不推荐用六氯酚和聚维酮碘进行局部去定植。也有证据支持使用选择性消化道去污和选择性口咽部去污,但需要更多研究来评估对这些药物的耐药性,尤其是革兰氏阴性菌中的耐药性选择。去定植的最有力证据是在外科患者中作为预防手术部位感染的策略使用。